Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer
Por:
Liu, K, Nicoletti, R, Zhao, HD, Chen, X, Wu, HW, Leung, CH, D'Andrea, D, Laukhtina, E, Soria, F, Gallioli, A, Wroclawski, ML, Castellani, D, Gauhar, V, Rivas, JG, Enikeev, D, Gontero, P, Shariat, SF, Chiu, PKF, Ng, CF, Teoh, JYC
Publicada:
27 sep 2024
Resumen:
Objective To investigate the impact of ageing on survival outcomes in Bacillus Calmette-Guerin (BCG) treated non-muscle invasive bladder cancer (NMIBC) patients and its synergy with adequate BCG treatment. Method Patients with NMIBC who received BCG treatment from 2001 to 2020 were divided into group 1 (< = 70 years) and group 2 (> 70 years). Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method. Multivariable Cox regression analysis was used to adjust potential confounding factors and to estimate Hazard Ratio (HR) and 95% Confidence Interval (CI). Subgroup analysis was performed according to adequate versus inadequate BCG treatment. Results Overall, 2602 NMIBC patients were included: 1051 (40.4%) and 1551 (59.6%) in groups 1 and 2, respectively. At median follow-up of 11.0 years, group 1 (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS as compared to group 2 (> 70 years). At subgroup analysis, patients in group 1 treated with adequate BCG showed better OS, CSS, RFS, and PFS as compared with inadequate BCG treatment in group 2, while patients in group 2 receiving adequate BCG treatment had 41% less progression than those treated with inadequate BCG from the same group. Conclusions Being younger (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS. Older patients (> 70 years) who received adequate BCG treatment had similar PFS as those younger with adequate BCG treatment.
Filiaciones:
Liu, K:
Chinese Univ Hong Kong, Prince Wales Hosp, SH Ho Urol Ctr,Fac Med, Dept Surg,Shatin, 4-F LCW Clin Sci Bldg, Hong Kong, Peoples R China
Nicoletti, R:
Chinese Univ Hong Kong, Prince Wales Hosp, SH Ho Urol Ctr,Fac Med, Dept Surg,Shatin, 4-F LCW Clin Sci Bldg, Hong Kong, Peoples R China
Univ Florence, Dept Expt Clin & Biomed Sci, Florence, Italy
Zhao, HD:
Chinese Univ Hong Kong, Prince Wales Hosp, SH Ho Urol Ctr,Fac Med, Dept Surg,Shatin, 4-F LCW Clin Sci Bldg, Hong Kong, Peoples R China
Chen, X:
Chinese Univ Hong Kong, Prince Wales Hosp, SH Ho Urol Ctr,Fac Med, Dept Surg,Shatin, 4-F LCW Clin Sci Bldg, Hong Kong, Peoples R China
Wu, HW:
Chinese Univ Hong Kong, Prince Wales Hosp, SH Ho Urol Ctr,Fac Med, Dept Surg,Shatin, 4-F LCW Clin Sci Bldg, Hong Kong, Peoples R China
Leung, CH:
Chinese Univ Hong Kong, Prince Wales Hosp, SH Ho Urol Ctr,Fac Med, Dept Surg,Shatin, 4-F LCW Clin Sci Bldg, Hong Kong, Peoples R China
D'Andrea, D:
Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
European Assoc Urol Young Acad Urologists EAU YAU, Urothelial Canc Working Grp, Amsterdam, Netherlands
Laukhtina, E:
Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
Soria, F:
Univ Studies Torino, San Giovanni Battista Hosp, Dept Surg Sci, Div Urol, I-10024 Turin, Italy
Gallioli, A:
European Assoc Urol Young Acad Urologists EAU YAU, Urothelial Canc Working Grp, Amsterdam, Netherlands
Autonoma Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain
Wroclawski, ML:
Hosp Israelita Albert Einstein, Dept Urol, Sao Paulo, Brazil
Hosp Beneficencia Portuguesa Sao Paulo, Dept Urol, Sao Paulo, Brazil
Fac Med ABC, Dept Urol, Santo Andre, Brazil
Castellani, D:
Univ Politecn Marche, Urol Unit, Azienda Osped Univ Marche, Ancona, Italy
Gauhar, V:
Natl Univ Hlth Syst, Ng Teng Fong Gen Hosp, Dept Urol, Singapore City, Singapore
Rivas, JG:
Clin San Carlos Univ Hosp, Dept Urol, Madrid, Spain
Enikeev, D:
Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
Karl Landsteiner Inst Urol & Androl, Vienna, Austria
Rabin Med Ctr, Div Urol, Petah Tiqwa, Israel
Gontero, P:
Univ Torino, Dept Urol, Citta Della Salute & Della Sci, Sch Med, Turin, Italy
Shariat, SF:
Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
Charles Univ Prague, Hosp Motol, Fac Med 2, Dept Urol, Prague, Czech Republic
Weill Cornell Med Coll, Dept Urol, New York, NY USA
Univ Texas Southwestern, Dept Urol, Dallas, TX USA
Al Ahliyya Amman Univ, Hourani Ctr Appl Sci Res, Amman, Jordan
Univ Montreal Hlth Ctr, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
Tabriz Univ Med Sci, Res Ctr Evidence Based Med, Iranian EBM Ctr, A Joanna Briggs Inst JBI,Ctr Excellence, Tabriz, Iran
Chiu, PKF:
Chinese Univ Hong Kong, Prince Wales Hosp, SH Ho Urol Ctr,Fac Med, Dept Surg,Shatin, 4-F LCW Clin Sci Bldg, Hong Kong, Peoples R China
Ng, CF:
Chinese Univ Hong Kong, Prince Wales Hosp, SH Ho Urol Ctr,Fac Med, Dept Surg,Shatin, 4-F LCW Clin Sci Bldg, Hong Kong, Peoples R China
Teoh, JYC:
Chinese Univ Hong Kong, Prince Wales Hosp, SH Ho Urol Ctr,Fac Med, Dept Surg,Shatin, 4-F LCW Clin Sci Bldg, Hong Kong, Peoples R China
Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
European Assoc Urol Young Acad Urologists EAU YAU, Urothelial Canc Working Grp, Amsterdam, Netherlands
hybrid
|